Jude  Onyia net worth and biography

Jude Onyia Biography and Net Worth

Jude Onyia, Ph.D. was appointed Chief Scientific Officer in November 2021 and leads the drug discovery and non-clinical development teams responsible for bolstering and advancing the company’s pipeline of therapeutic candidates. Additionally, in the beginning of 2023, Dr. Onyia joined Voyager Therapeutics, Inc.’s board of directors. A scientist with more than 25 years of experience in the pharmaceutical industry, Dr. Onyia is the former Vice President of Biotechnology Discovery Research at Eli Lilly and Company. At Lilly, Dr. Onyia contributed to the discovery and/or advancement of more than 60 clinical candidates across multiple therapeutic areas, which led to seven approved medicines. He also was responsible for more than 50 pre-candidate programs across multiple therapeutic areas. Dr. Onyia holds a B.S. in Forest Biology from the State University of New York (SUNY) College of Environmental Science and Forestry, as well as a Ph.D. in Cell and Molecular Biology from the SUNY Health Science Center, both at Syracuse, NY.

What is Jude Onyia's net worth?

The estimated net worth of Jude Onyia is at least $1.38 million as of November 29th, 2023. Dr. Onyia owns 11,732 shares of Neurocrine Biosciences stock worth more than $1,375,929 as of December 10th. This net worth evaluation does not reflect any other assets that Dr. Onyia may own. Additionally, Dr. Onyia receives an annual salary of $621,660.00 as Insider at Neurocrine Biosciences. Learn More about Jude Onyia's net worth.

How old is Jude Onyia?

Dr. Onyia is currently 59 years old. There are 7 older executives and no younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences is Dr. Kevin C. Gorman Ph.D., CEO & Director, who is 65 years old. Learn More on Jude Onyia's age.

What is Jude Onyia's salary?

As the Insider of Neurocrine Biosciences, Inc., Dr. Onyia earns $621,660.00 per year. There are 6 executives that earn more than Dr. Onyia. The highest earning executive at Neurocrine Biosciences is Dr. Kevin C. Gorman Ph.D., CEO & Director, who commands a salary of $1,900,000.00 per year. Learn More on Jude Onyia's salary.

How do I contact Jude Onyia?

The corporate mailing address for Dr. Onyia and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected]. Learn More on Jude Onyia's contact information.

Has Jude Onyia been buying or selling shares of Neurocrine Biosciences?

Within the last three months, Jude Onyia has sold $264,731.67 in shares of Neurocrine Biosciences stock. Most recently, Jude Onyia sold 2,331 shares of the business's stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $113.57, for a transaction totalling $264,731.67. Following the completion of the sale, the insider now directly owns 11,732 shares of the company's stock, valued at $1,332,403.24. Learn More on Jude Onyia's trading history.

Who are Neurocrine Biosciences' active insiders?

Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Ingrid Delaet (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), Jude Onyia (Insider), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.

Are insiders buying or selling shares of Neurocrine Biosciences?

During the last year, Neurocrine Biosciences insiders bought shares 1 times. They purchased a total of 4,395,588 shares worth more than $39,032,821.44. During the last year, insiders at the sold shares 28 times. They sold a total of 176,946 shares worth more than $19,517,697.56. The most recent insider tranaction occured on December, 6th when insider Darin Lippoldt sold 20,830 shares worth more than $2,496,683.80. Insiders at Neurocrine Biosciences own 4.4% of the company. Learn More about insider trades at Neurocrine Biosciences.

Information on this page was last updated on 12/6/2023.

Jude Onyia Insider Trading History at Neurocrine Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/29/2023Sell2,331$113.57$264,731.6711,732View SEC Filing Icon  
8/21/2023Sell3,198$107.37$343,369.269,638View SEC Filing Icon  
See Full Table

Jude Onyia Buying and Selling Activity at Neurocrine Biosciences

This chart shows Jude Onyia's buying and selling at Neurocrine Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Neurocrine Biosciences Company Overview

Neurocrine Biosciences logo
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $117.28
Low: $117.23
High: $120.32

50 Day Range

MA: $112.36
Low: $106.07
High: $120.00

2 Week Range

Now: $117.28
Low: $89.04
High: $125.01


528,392 shs

Average Volume

732,433 shs

Market Capitalization

$11.52 billion

P/E Ratio


Dividend Yield